KalVista Pharmaceuticals, Inc.
$26.95
+0.037%KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -8.3).
Valuation inputs: P/E -8.3, earnings yield N/A, momentum +0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +60.6%, ROIC -58.9%).
Profitability stack: net margin -2.2%, ROE +60.6%, ROIC -58.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +100.8%, momentum +0.0%, net margin -2.2%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
KalVista Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
KalVista Pharmaceuticals, Inc. Fair Value Envelope
KalVista Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
KalVista Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
KalVista Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
KalVista Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that KALV stock may experience modest gains over the coming 12 months. The consensus 1-year price target stands at 28.67, with estimates ranging from a low of 27.00 to a high of 32.00.
The consensus 1-year price target stands at 28.67, with estimates ranging from a low of 27.00 to a high of 32.00.
Analyst Consensus Analysis
Upside Potential
Moderate upside. Analysts expect positive returns but with limited margin of safety. Consider entry timing.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
KalVista Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $3.50M and sold $7.99M worth of KALV shares, resulting in $4.49M of net selling activity.
3 Months
0
0.00
262.5K
5.14M
-5.1M
-$5.14M
3-6 Months
0
0.00
39.4K
619.32K
-619K
-$619K
6-9 Months
295.0K
3.50M
49.7K
690.08K
+2.8M
+$2.81M
9-12 Months
0
0.00
104.3K
1.54M
-1.5M
-$1.54M
Top Buyers
Arif Bilal
Officer: Chief Operations Officer
$1.15M
Sensenig Bethany
Director
$542K
Fairey William
Director
$362K
Unkart Edward W
Director
$362K
Treanor Patrick
Director
$362K
Top Sellers
Venrock Healthcare Capital Partners Iii, L.P.
10 Percent Owner
$2.96M
Palleiko Benjamin L
Director, Officer: Chief Executive Officer
$2.25M
Yea Christopher
Officer: Chief Development Officer
$1.80M
Audhya Paul K.
Officer: Chief Medical Officer
$539K
Sweeny Nicole
Officer: Chief Commercial Officer
$285K
Insider Activity Analysis
Net Insider Sentiment
Negative insider sentiment with $4.49M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
KALV has not reported any dividend yield values in the available annual periods.
kalv Dividend History
Learning Layer
Related Guides
Build conviction on KALV by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.